DLA Piper advised Ascentage Pharma Group International (Ascentage Pharma), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancer, in raising US$192.3 million through an oversubscribed offshore top-up share placement.
Ascentage Pharma intends to use the net proceeds for commercialization efforts, including expanding coverage and improving patient access, global clinical development to advance the core pipeline candidates of the company, as well as infrastructure and working capital to strengthen global operations.
The DLA Piper deal team was led by Partner Era Anagnosti (Washington, DC) and included Partners Christopher Paci (New York) and Emilio Ragosa (Short Hills), and Of Counsel Amanda Maki (Houston).
With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 15 consecutive years, according to Mergermarket, and ranked as number one in VC, PE and M&A in combined global deal volume according to PitchBook.